Article
Author(s):
Philadelphia-In an uncertain economic climate, the ophthalmic market can take stock in knowing it is alive and well, according to Kenneth P. Taylor, an independent industry consultant.
4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment
ROP: Treating and preventing blindness in preterm babies
Early vision screening is key to slowing myopia progression in children
Managing a changing landscape of IRD pediatric cases
Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease
Cerebral visual impairment is a growing concern in pediatric vision loss